Apollomics enrolls first patient in Phase 3 trial of leukemia drug
Category: #health  By Mateen Dalal  Date: 2021-11-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

Apollomics enrolls first patient in Phase 3 trial of leukemia drug

GlycoMimetics, Inc., a firm that develops molecule drugs, has recently announced that biotech company Apollomics has dosed first patient in China in a Phase 3 clinical trial of its new relapsed or refractory acute myeloid leukemia (AML) drug, APL-106 (uproleselan injection).

The Phase 3 clinical trial is part of a randomized, placebo-controlled, double-blind, bridging study program that will assess the effectiveness of uproleselan combined with chemotherapy, compared to alone chemotherapy, for treating people suffering from relapsed/refractory AML in Chinese patients.

The trial is a part of a complete development program for Apollomics in China, including a continuing Phase 1 pharmacokinetic (PK) and tolerability study.

According to sources, around 140 adult patients with primary relapsed AML (first or second untreated relapse) or refractory AML, will be enrolled for trial and eligible to receive induction chemotherapy.

Harout Semerjian, GlycoMimetics Chief Executive Officer, said that dosing of the first patient in this Phase 3 clinical trial in Greater China is a noteworthy accomplishment for Apollomics. This achievement comes in line with the recent completion of enrollment in a pivotal Phase 3 trial studying uproleselan in addition to a standard chemotherapy routine in patients with relapsed/refractory AML.

The prime endpoint for the Phase 3 trial is overall existence. Secondary outcome procedures include the duration and rate of remission and if uproleselan could lower the rate of oral mucositis, a chemotherapy-related side effect.

Apollomics expects to perform this study at around 20 blood cancer clinical research centers across China.

About Apollomics Inc.

Apollomics Inc. is a pioneering biopharmaceutical company devoted to discovering and developing monotherapies and combination therapies of tumor-targeting and immuno-oncology agents. Apollomics has influential entities in California’s Foster City, and Hangzhou and Shanghai in China.

Source Credit - https://www.businesswire.com/news/home/20211123006145/en/ApollomicApollomics%20Inc.s-Inc.-Doses-First-Patient-in-Phase-3-Clinical-Trial-in-China-of-GlycoMimetics%E2%80%99-Uproleselan-for-the-Treatment-of-AML

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Facebook and Instagram owner Meta to lay off 10,000 jobs to cut costs
Facebook and Instagram owner Meta to lay off 10,000 jobs to cut costs
By Mateen Dalal

Meta, the leading American technology company and the owner of social media platforms Facebook and Instagram, has reportedly announced its plans to lay off around 10,000 employees. Apparently, this is going to be the second round of significant la...

Heathrow to lower passenger charges to feed through to the ticket prices
Heathrow to lower passenger charges to feed through to the ticket prices
By Mateen Dalal

Heathrow Airport, the U.K.’s leading international airport, has reportedly been advised to reduce passenger costs for airlines next year, as they would have an impact on ticket pricing. The Civil Aviation Authority (CAA) determined that lowe...

Amazon signs deal with mortgage lender Better.com to give employee benefits
Amazon signs deal with mortgage lender Better.com to give employee benefits
By Mateen Dalal

Amazon, the U.S.-based e-commerce giant, has reportedly inked a deal with struggling mortgage lender, Better.com to provide better perks to employees. For the unversed, Better.com is introducing Equity Unlocker, a product that enables staff member...